Lupin gets U.S. FDA nod for Prucalopride Tablets for treatment of CIC in adults
The approved product will be manufactured at Lupin's state-of-the-art facility in Goa, India.
Prucalopride Tablets are used for the treatment of chronic idiopathic constipation (CIC) in adults, a condition that causes difficult or infrequent bowel movements without a known cause. The drug works by stimulating bowel movements through selective serotonin 5-HT4 receptor agonism.
According to IQVIA MAT data for April 2025, Prucalopride Tablets (1 mg and 2 mg) had estimated annual sales of USD 184 million in the U.S., highlighting the strong market potential for Lupin's generic version.
This approval reinforces Lupin's position as a leading provider of high-quality, affordable generics in the U.S. pharmaceutical market.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Time Business News
2 days ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
2 days ago
- Yahoo
U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034
The U.S. pharmaceutical CDMO market is estimated at USD 39.14 billion in 2025 and is projected to reach approximately USD 68.57 billion by 2034, expanding at a CAGR of 6.43% over the forecast period. Ottawa, Aug. 13, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister firm of Precedence Research, the U.S. pharmaceutical CDMO market was valued at USD 36.77 billion in 2024 and is projected to reach approximately USD 68.57 billion by 2034, growing at a CAGR of 6.43%. The rising commercial scale-up in different therapeutic areas in the US and growing adoption of digital technologies are fueling overall market expansion. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways By product, the API segment dominated the U.S. pharmaceutical CDMO market in 2024 and is expected to grow fastest during the forecast period. By workflow, the commercial segment held the largest revenue share of the market in 2024. By application, the oncology segment registered dominance in the market in 2024. By end-use, the large pharmaceutical companies segment was dominant in the U.S. pharmaceutical CDMO market in 2024 and is expected to grow rapidly in the studies years. Market Overview & Potential Companies that are offering comprehensive services to different pharmaceutical and biotechnology companies, including both drug development and manufacturing in the US, are referred to as U.S. pharmaceutical CDMO market. Primarily, they provide expertise and resources for these companies. In 2025, they are focusing on novel drug discovery and development in oncology and other chronic conditions with the increased adoption of advanced production technologies. Moreover, the US is widely investing in robust and advanced infrastructure to fulfil the requirements of the increasing demand for specialized services, particularly in areas like biologics, sterile injectables, and gene and cell therapies. What are the Key Drivers Involved in The Growth of The Market? The U.S. pharmaceutical CDMO market has major dominating factors in its expansion, including crucial support to small and mid-sized pharmaceutical companies. These companies are facing the limitations of infrastructure for large-scale production with enhanced dependence on CDMOs for numerous stages of development and manufacturing. Also, benefits of pharmaceutical CDMOs, like scalability, flexibility, and cost-effectiveness, are fueling the expansion of the market with reduced capital investments. Besides this, experts working in CDMOs can navigate the complex regulatory landscape and check the compliance with standards like GMP (Good Manufacturing Practices). What are the Trends Associated with the U.S. Pharmaceutical CDMO Market? Different companies in the US are highly adopting outsourcing production to CDMOs to handle expenses and emphasis on competencies. Alongside, continuous advances in technologies and regulatory frameworks also play a crucial role in this market development. In May 2025, CDMO Piramal Pharma Solutions announced $90 million investment into its US manufacturing facilities. In March 2025, LGM Pharma, a global provider of customized API and CDMO services for the full drug product lifecycle, invested $6M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Emerging Challenge in the Market? Challenges connected with the U.S. pharmaceutical CDMO market include geopolitical stress, lack of raw material, and pandemic-related disturbances, are contribute as barriers in the production and delivery. Along with this, the rising need for a skilled workforce and specialized knowledge in continuous manufacturing and advanced bioprocessing demands vital investment in training and development. Country-level Analysis The U.S. pharmaceutical CDMO market is experiencing widespread expansion due to broader demand for a variety of biologics and biosimilars which are used in novel rare cases and other severe health issues. Besides this, ongoing technological breakthroughs in process chemistry and manufacturing automation are boosting the efficiency and quality of drug production, further propelling the adoption of CDMO services. As well as escalating cases of diverse cancers is assisting the development of novel cancer therapies, including targeted therapies and immunotherapies. For this market, In June 2025, Agenus Inc., a U.S.-based biotechnology company specializing in immuno-oncology, entered into a partnership with $141M Zydus investment to transform the immune-oncology area. Segmental Insights By product analysis How did the API Segment Lead the U.S. Pharmaceutical CDMO Market in 2024? The API segment was dominant in the market in 2024 and will grow rapidly during 2025-2034. An escalating demand for both traditional and complex APIs, especially in small molecule drugs, is fueling the segment's growth. In this segment, synthetic APIs experienced major demand, which are highly employed in numerous therapeutic areas such as cardiovascular, analgesic, and CNS drugs, making them an important driver in the API CDMO market. Also, this segment is moving towards continuous manufacturing, process analytical technology (PAT), sustainability, and digitalization, with enhanced focus on specialized CDMOs catering to niche therapeutic areas and expansion in biotech API development. Become a valued research partner with us - By workflow analysis What Made the Commercial Segment Dominant in the Market in 2024? In the U.S. pharmaceutical CDMO market, the commercial segment captured a major revenue share in 2024. Across the globe, one of the vital factors contributing to the overall market expansion is improved focus on the large-scale manufacturing of pharmaceuticals and biopharmaceuticals for commercial distribution. Moreover, widespread involvement of specialized expertise in biologics, cell & gene therapies, and mRNA vaccines necessitates sophisticated and specialized manufacturing capabilities. Additionally, CDMOs are boosting their service offerings by expanding collaboration with other organizations and companies to incorporate the complete drug development and manufacturing lifecycle, from early development to commercial launch. By application analysis How did Oncology Dominate the U.S. Pharmaceutical CDMO Market in 2024? The oncology segment registered dominance with the biggest share of the market in 2024. Eventual growth in cancer cases, with the progression of personalized therapies and targeted treatments, is impacting segment expansion. US CDMOs are stepping towards the transformation of advanced therapies, especially cell and gene therapies, antibody-drug conjugates, and bispecific antibodies, which are a major part of oncology clinical trials. These therapies are widely propelling demand for specialized facilities and expertise in handling potent APIs, cytotoxic compounds, and sterile injectables. By end-use analysis How did the Large Pharmaceutical Companies Hold a Major Share of The Market in 2024? The large pharmaceutical companies segment led the U.S. pharmaceutical CDMO market in 2024 and is anticipated to witness the fastest growth during 2025-2034. Nowadays, a rise in innovation investments, mainly in data analytics and AI, is assisting overall drug development processes and ultimately enhancing productivity. Apart from this, these companies are focusing on the utilization of advanced formulation technologies in specific areas, especially oral peptide formulations and permeation enhancers, to optimize drug delivery. These companies frequently grasp their robust infrastructure, scientific expertise, and global networks, which make them attractive for further collaborations and outsourcing to CDMOs in the US. Get the latest insights on healthcare industry segmentation with our Annual Membership: Ongoing Developments in the U.S. Pharmaceutical CDMO Market In July 2025, ESTEVE acquired Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), to accelerate its contract development and manufacturing services for small-molecule active pharmaceutical ingredients from pre-clinical to commercial manufacturing in the US. In May 2025, Purdue University and a collaboration of leaders in AI, pharmaceutical manufacturing, and public policy launched a national effort in the Dirksen Senate Office Building to boost pharmaceutical manufacturing in the United States by revealing cutting-edge AI and advanced manufacturing technologies. In May 2025, Benuvia Operations, LLC, a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier, signed a multi-year supply agreement with a prominent U.S. pharmaceutical company to support the company's product development activities. Key Players in the U.S. Pharmaceutical CDMO Market Adare Pharma Solutions AGC Biologics Agilent Technologies Catalent Pharma Solutions Exela Pharma Sciences PCI Pharma Services Pfizer CentreOne Scorpius BioManufacturing Sharp Services Single Use Support Thermo Fisher Scientific UPM Pharmaceuticals, Inc. Browse More Insights of Towards Healthcare: The global bioconjugation market reached USD 5.52 billion in 2024, rose to USD 6.37 billion in 2025, and will likely hit USD 23.18 billion by 2034, expanding at a CAGR of 15.46% from 2025 to 2034. The U.S. residual DNA testing market continues its upward trajectory and is set to generate substantial revenue growth, potentially reaching hundreds of millions by 2034. The worldwide life science CDMO market is expanding significantly and is projected to record several hundred million dollars in additional revenue by the end of the forecast period from 2025 to 2034. The global veterinary CRO and CDMO market stood at USD 7.17 billion in 2024, increased to USD 7.77 billion in 2025, and will likely reach USD 16.13 billion by 2034, growing at a CAGR of 8.43% between 2025 and 2034. The global investigational new drug CDMO market measured USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is forecast to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% during the same period. The global advanced therapy medicinal products CDMO market stood at USD 6.73 billion in 2024, grew to USD 7.99 billion in 2025, and will likely surge to USD 37.27 billion by 2034, posting a CAGR of 18.82% between 2025 and 2034. The global mRNA therapeutics CDMO market valued at USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to reach USD 13.63 billion by 2034, growing at a CAGR of 11.37% from 2025 to 2034. The CDMO services for pharma and biotech market is posting substantial growth from 2024 to 2034, fueled by rising outsourcing trends among pharmaceutical and biotech companies. The CDMO aseptic filling solutions market is recording robust growth and will continue booming through the forecast period, driven by growing demand for sterile manufacturing and specialized injectable therapies. The active pharmaceutical ingredients CDMO market stood at USD 127.45 billion in 2024, rose to USD 136.92 billion in 2025, and is projected to reach USD 260.98 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. Segments Covered in The Report By Product API Type Traditional API Highly Potent API Antibody-drug conjugate (ADC) Others Synthesis Synthetic Solid Liquid Biotech Drug Innovative Generics Manufacturing Continuous Manufacturing Batch Manufacturing Drug Product Oral Solid Dose Semi-Solid Dose Liquid Dose Others By Workflow Commercial Clinical By Application Oncology Small Molecules Biologics Infectious Diseases Neurological Disorders Cardiovascular Disease Metabolic Disorders Autoimmune Diseases Respiratory Diseases Ophthalmology Gastrointestinal Disorders Hormonal Disorders Hematological Disorders Others By End-Use Large Pharmaceutical Companies Medium Pharmaceutical Companies Small Pharmaceutical Companies Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
